The use of two or more HMG-CoA reductase inhibitors in combination is not justified. Additional therapeutic benefit is not realized when HMG-CoA reductase inhibitors are used concomitantly and may result in increased adverse reactions such as myopathy and rhabdomyolysis. Patients receiving multiple HMG-CoA reductase inhibitors concurrently will be reviewed.